Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.

A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

Janet Figge donates painting to The University of Kansas Cancer Center at the St. Francis Campus to honor her late husband's ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...